Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tracy L Taylor

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|August 5, 2009
Periodic, partial inhibition of IkappaB Kinase beta-mediated signaling yields therapeutic benefit in preclinical models of rheumatoid arthritisKathleen M Gillooly, Mark A Pattoli, Tracy L Taylor, et al.
ACS Medicinal Chemistry Letters|September 18, 2020
Aryl Ether-Derived Sphingosine-1-Phosphate Receptor (S1P<sub>1</sub>) Modulators: Optimization of the PK, PD, and Safety ProfilesZili Xiao, Michael G Yang, T G Murali Dhar, et al.
Bioorganic & Medicinal Chemistry Letters|March 4, 2008
The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitorJohn Hynes, Hong Wu, Sidney Pitt, et al.
Journal of Medicinal Chemistry|January 25, 2021
Bicyclic Ligand-Biased Agonists of S1P<sub>1</sub>: Exploring Side Chain Modifications to Modulate the PK, PD, and Safety ProfilesJohn L Gilmore, Hai-Yun Xiao, T G Murali Dhar, et al.
Journal of Medicinal Chemistry|September 12, 2015
Discovery of ((4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methylpyrrolo[1,2-f][1,2,4]triazine-6-carbonyl)(propyl)carbamoyloxy)methyl-2-(4-(phosphonooxy)phenyl)acetate (BMS-751324), a Clinical Prodrug of p38α MAP Kinase InhibitorChunjian Liu, James Lin, John Hynes, et al.
ACS Medicinal Chemistry Letters|March 21, 2019
Identification of Imidazo[1,2-<i>b</i>]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 InhibitorsChunjian Liu, James Lin, Ryan Moslin, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical TrialsT G Murali Dhar, Hai-Yun Xiao, Jenny Xie, et al.
Medchemcomm|August 16, 2018
Identification of potent tricyclic prodrug S1P<sub>1</sub> receptor modulatorsDavid Marcoux, Hai-Yun Xiao, T G Murali Dhar, et al.
Journal of Medicinal Chemistry|December 23, 2016
Asymmetric Hydroboration Approach to the Scalable Synthesis of ((1R,3S)-1-Amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986104) as a Potent S1P<sub>1</sub> Receptor ModulatorMichael G Yang, Zili Xiao, T G Murali Dhar, et al.
ACS Medicinal Chemistry Letters|November 20, 2020
Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTKAnurag S Srivastava, Soo Ko, Scott H Watterson, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
The Journal of Pharmacology and Experimental Therapeutics|August 5, 2009
Periodic, partial inhibition of IkappaB Kinase beta-mediated signaling yields therapeutic benefit in preclinical models of rheumatoid arthritisKathleen M Gillooly, Mark A Pattoli, Tracy L Taylor, et al.
ACS Medicinal Chemistry Letters|September 18, 2020
Aryl Ether-Derived Sphingosine-1-Phosphate Receptor (S1P<sub>1</sub>) Modulators: Optimization of the PK, PD, and Safety ProfilesZili Xiao, Michael G Yang, T G Murali Dhar, et al.
Bioorganic & Medicinal Chemistry Letters|March 4, 2008
The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitorJohn Hynes, Hong Wu, Sidney Pitt, et al.
Journal of Medicinal Chemistry|January 25, 2021
Bicyclic Ligand-Biased Agonists of S1P<sub>1</sub>: Exploring Side Chain Modifications to Modulate the PK, PD, and Safety ProfilesJohn L Gilmore, Hai-Yun Xiao, T G Murali Dhar, et al.
Journal of Medicinal Chemistry|September 12, 2015
Discovery of ((4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methylpyrrolo[1,2-f][1,2,4]triazine-6-carbonyl)(propyl)carbamoyloxy)methyl-2-(4-(phosphonooxy)phenyl)acetate (BMS-751324), a Clinical Prodrug of p38α MAP Kinase InhibitorChunjian Liu, James Lin, John Hynes, et al.
ACS Medicinal Chemistry Letters|March 21, 2019
Identification of Imidazo[1,2-<i>b</i>]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 InhibitorsChunjian Liu, James Lin, Ryan Moslin, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical TrialsT G Murali Dhar, Hai-Yun Xiao, Jenny Xie, et al.
Medchemcomm|August 16, 2018
Identification of potent tricyclic prodrug S1P<sub>1</sub> receptor modulatorsDavid Marcoux, Hai-Yun Xiao, T G Murali Dhar, et al.
Journal of Medicinal Chemistry|December 23, 2016
Asymmetric Hydroboration Approach to the Scalable Synthesis of ((1R,3S)-1-Amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986104) as a Potent S1P<sub>1</sub> Receptor ModulatorMichael G Yang, Zili Xiao, T G Murali Dhar, et al.
ACS Medicinal Chemistry Letters|November 20, 2020
Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTKAnurag S Srivastava, Soo Ko, Scott H Watterson, et al.
Pageof 6